Trofinetide

(Daybue®)

Daybue®

Drug updated on 12/19/2023

Dosage FormOral solution (oral: 200 mg/mL)
Drug ClassGlypromate analog
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.

Product Monograph / Prescribing Information

Document TitleYearSource
Daybue (trofinetide) Prescribing Information. 2023Acadia Pharmaceuticals Inc. San Diego, CA

Randomized Controlled Trials


Sex Distribution:

F:100%
M:0%
187Subjects

Year:

2023

Source:Nature Medicine


Sex Distribution:

F:100%
M:0%
187Subjects

Year:

2022

Source:Contemporary Clinical Trials


Sex Distribution:

F:100%
M:0%
82Subjects

Year:

2019

Source:Neurology


Sex Distribution:

F:100%
M:0%
56Subjects

Year:

2017

Source:Pediatric Neurology